> Despite falling sales and a so-far failed effort to find a buyer, Dendreon ($DNDN) continues to pursue new research into biomarkers that could be used to guide the use of Provenge. Story
> Exagen Diagnostics has nailed down a loan for up to $25 million that will help the company expand sales efforts for its rheumatology tests. Report
> A new report from Decision Resources concludes that while biomarkers have been most useful in oncology, they are also playing a growing role for chronic conditions. Release